Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 1121 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2.Enlace a cita original Cita con resumen
Kaufman DW, Kelly JP, Battista DR, Malone MK, Weinstein RB, Shiffman S. Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users. Pharmacoepidemiol Drug Saf 2018;27:marzo. [Ref.ID 102633]
3.Enlace a cita original Cita con resumen
Salm-Reifferscheidt L. Tramadol: Africa's opioid crisis. Lancet 2018;391:19 de mayo. [Ref.ID 102613]
4.Enlace a cita original Cita con resumen
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM, for the GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018;378:17 de mayo. [Ref.ID 102609]
5.Enlace a cita original Cita con resumen
Lanoiselée J, Zufferey PJ, Ollier E, Hoding S, Delavenne X, for the PeriOpeRative Tranexamic acid in hip arthrOplasty (PORTO) study investigators. Is tranexamic acid exposure related to blood loss in hip arthroplasty? A pharmacokinetic–pharmacodynamic study . Br J Clin Pharmacol 2018;84:febrero. [Ref.ID 102534]
6. Cita con resumen
Shardlow A, McIntyre NJ, Fraser SDS, Roderick P, Raftery J, Fluck RJ, McIntyre CW, Taal MW. The clinical utility and cost impact of cystatin C measurement in the diagnosis and management of chronic kidney disease: A primary care cohort study. PLOS Medicine 2017:10 de octubre. [Ref.ID 102114]
7. Cita con resumen
Anónimo. FDA warns about serious liver injury with Ocaliva (obeticholic acid) for rare chronic liver disease. FDA U.S. Food and Drug Administration 2017:21 de septiembre. [Ref.ID 102061]
8. Cita con resumen
Grosser T, Ricciotti E, Fitzgerald GA. The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 2017;38:733-48. [Ref.ID 101990]
9. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
10. Cita con resumen
Kesselheim AS, Donneyong M, Dal Pan GJ, Zhou EH, Avorn J, Schneeweiss S, Seeger JD. Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf 2017;26:712-21. [Ref.ID 101627]
11. Cita con resumen
Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]
12. Cita con resumen
Anónimo. ‘Sí’ de la UE a un antipsicótico de Janssen de acción larga. Correo Farmacéutico 2016:17. [Ref.ID 100408]
13. Cita con resumen
Greene MF, Drazen JM. A new label for mifepristone. N Engl J Med 2016;374:2281-2. [Ref.ID 100400]
15.Tiene citas relacionadas Cita con resumen
Katz MH. Opioid prescribing for chronic pain. Not for the faint of heart . JAMA Intern Med 2016;176:599-601. [Ref.ID 100104]
16.Enlace a cita original Cita con resumen
Hayward KL, Powell EE, Irvine KM, Martin JH. Can paracetamol (acetaminophen) be administered to patients with liver impairment?. Br J Clin Pharmacol 2016;81:210-22. [Ref.ID 100097]
17. Cita con resumen
Cohen D. Rivaroxaban: can we trust the evidence?. BMJ 2016;352:i575. [Ref.ID 100048]
18.Enlace a cita originalTiene citas relacionadas Cita con resumen
Dowell D, Haegerich TM. CDC guideline for prescribing opioids for chronic pain — United States, 2016. JAMA 2016;315:15 de marzo. [Ref.ID 100030]
19. Cita con resumen
Anónimo. Thalidomide: reduced starting dose in patients older than age 75 years. Drug Safety Update 2015;9:2. [Ref.ID 99746]
20. Cita con resumen
Caverly TJ, Fagerlin A, Zikmund-Fisher BJ, Kirsh S, Kullgren JT, Prenovost K, Kerr EA. Appropriate prescribing for patients with diabetes at high risk for hypoglycemia. National Survey of Veterans Affairs health care professionals . JAMA Intern Med 2015;175:1994-6. [Ref.ID 99660]
Seleccionar todas
 
 1 a 20 de 1121 siguiente >>